Literature DB >> 31481523

Structure-function guided modeling of chemokine-GPCR specificity for the chemokine XCL1 and its receptor XCR1.

Jamie C Fox1, Monica A Thomas1, Acacia F Dishman1, Olav Larsen2, Takashi Nakayama3, Osamu Yoshie4, Mette Marie Rosenkilde2, Brian F Volkman5.   

Abstract

Chemokines interact with their G protein-coupled receptors (GPCRs) through a two-step, two-site mechanism and, through this interaction, mediate various homeostatic and immune response mechanisms. Upon initial recognition of the chemokine by the receptor, the amino terminus of the chemokine inserts into the orthosteric pocket of the GPCR, causing conformational changes that trigger intracellular signaling. There is considerable structural and functional evidence to suggest that the amino acid composition and length of the chemokine amino terminus is critical for GPCR activation, complementing the size and amino acid composition of the orthosteric pocket. However, very few structures of a native chemokine-receptor complex have been solved. Here, we used a hybrid approach that combines structure-function data with Rosetta modeling to describe key contacts within a chemokine-GPCR interface. We found that the extreme amino-terminal residues of the chemokine XCL1 (Val1, Gly2, Ser3, and Glu4) contribute a large fraction of the binding energy to its receptor XCR1, whereas residues near the disulfide bond-forming residue Cys11 modulate XCR1 activation. Alterations in the XCL1 amino terminus changed XCR1 activation, as determined by assessing inositol triphosphate accumulation, intracellular calcium release, and directed cell migration. Computational analysis of XCL1-XCR1 interactions revealed functional contacts involving Glu4 of XCL1 and Tyr117 and Arg273 of XCR1. Subsequent mutation of Tyr117 and Arg273 led to diminished binding and activation of XCR1 by XCL1. These findings demonstrate the utility of a hybrid approach, using biological data and homology modeling, to study chemokine-GPCR interactions.
Copyright © 2019 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31481523      PMCID: PMC6733756          DOI: 10.1126/scisignal.aat4128

Source DB:  PubMed          Journal:  Sci Signal        ISSN: 1945-0877            Impact factor:   8.192


  85 in total

Review 1.  Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling.

Authors:  S S Ferguson
Journal:  Pharmacol Rev       Date:  2001-03       Impact factor: 25.468

Review 2.  Cell migration/chemotaxis: biphasic dose responses.

Authors:  E J Calabrese
Journal:  Crit Rev Toxicol       Date:  2001-07       Impact factor: 5.635

3.  Structural rearrangement of human lymphotactin, a C chemokine, under physiological solution conditions.

Authors:  E Sonay Kuloğlu; Darrell R McCaslin; John L Markley; Brian F Volkman
Journal:  J Biol Chem       Date:  2002-03-11       Impact factor: 5.157

4.  Lymphotactin expression by engineered myeloma cells drives tumor regression: mediation by CD4+ and CD8+ T cells and neutrophils expressing XCR1 receptor.

Authors:  C M Cairns; J R Gordon; F Li; M E Baca-Estrada; T Moyana; J Xiang
Journal:  J Immunol       Date:  2001-07-01       Impact factor: 5.422

5.  Adenoviral vectors expressing lymphotactin and interleukin 2 or lymphotactin and interleukin 12 synergize to facilitate tumor regression in murine breast cancer models.

Authors:  P C Emtage; Y Wan; M Hitt; F L Graham; W J Muller; A Zlotnik; J Gauldie
Journal:  Hum Gene Ther       Date:  1999-03-20       Impact factor: 5.695

6.  Crystal structure of recombinant native SDF-1alpha with additional mutagenesis studies: an attempt at a more comprehensive interpretation of accumulated structure-activity relationship data.

Authors:  Y Ohnishi; T Senda; N Nandhagopal; K Sugimoto; T Shioda; Y Nagal; Y Mitsui
Journal:  J Interferon Cytokine Res       Date:  2000-08       Impact factor: 2.607

7.  Enhanced therapeutic efficacy of tumor RNA-pulsed dendritic cells after genetic modification with lymphotactin.

Authors:  W Zhang; L He; Z Yuan; Z Xie; J Wang; H Hamada; X Cao
Journal:  Hum Gene Ther       Date:  1999-05-01       Impact factor: 5.695

8.  Identification of viral macrophage inflammatory protein (vMIP)-II as a ligand for GPR5/XCR1.

Authors:  L Shan; X Qiao; E Oldham; D Catron; H Kaminski; D Lundell; A Zlotnik; E Gustafson; J A Hedrick
Journal:  Biochem Biophys Res Commun       Date:  2000-02-24       Impact factor: 3.575

9.  Adenovirus-mediated lymphotactin gene transfer improves therapeutic efficacy of cytosine deaminase suicide gene therapy in established murine colon carcinoma.

Authors:  D W Ju; Q Tao; D S Cheng; W Zhang; M Zhang; H Hamada; X Cao
Journal:  Gene Ther       Date:  2000-02       Impact factor: 5.250

10.  Monomeric solution structure of the prototypical 'C' chemokine lymphotactin.

Authors:  E S Kuloglu; D R McCaslin; M Kitabwalla; C D Pauza; J L Markley; B F Volkman
Journal:  Biochemistry       Date:  2001-10-23       Impact factor: 3.162

View more
  3 in total

Review 1.  Role of chemokine systems in cancer and inflammatory diseases.

Authors:  Hongyi Li; Min Wu; Xia Zhao
Journal:  MedComm (2020)       Date:  2022-06-08

2.  Efficient targeting of NY-ESO-1 tumor antigen to human cDC1s by lymphotactin results in cross-presentation and antigen-specific T cell expansion.

Authors:  Camille Le Gall; Anna Cammarata; Lukas de Haas; Iván Ramos-Tomillero; Jorge Cuenca-Escalona; Kayleigh Schouren; Zacharias Wijfjes; Anouk M D Becker; Johanna Bödder; Yusuf Dölen; I Jolanda M de Vries; Carl G Figdor; Georgina Flórez-Grau; Martijn Verdoes
Journal:  J Immunother Cancer       Date:  2022-04       Impact factor: 12.469

Review 3.  Recent Progress in Dendritic Cell-Based Cancer Immunotherapy.

Authors:  Kazuhiko Matsuo; Osamu Yoshie; Kosuke Kitahata; Momo Kamei; Yuta Hara; Takashi Nakayama
Journal:  Cancers (Basel)       Date:  2021-05-20       Impact factor: 6.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.